Population Pharmacokinetics (PK) of Melphalan in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Locations

1 United States site

Age

< 17 Years

Study type

Observational

Gender

All

Compensation

Unknown

About the study

Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of
this study is to determine what causes some children to have different drug concentrations of
melphalan in their bodies and if drug levels are related to whether or not a child
experiences severe side-effects during their bone marrow transplant. The hypothesis is that
certain clinical and individual factors cause changes in melphalan drug levels in pediatric
bone marrow transplant patients and that high levels may cause severe side-effects.

participation requirements

– Children 0-17 years of age

– Undergoing alloHCT for the treatment of malignant or nonmalignant disorder

– Receiving melphalan-based preparative regimen

participation restrictions

– Any child 7-17 years of age unwilling to provide assent

Locations

  • San Francisco, California, United States, University of California, San Francisco, 94143